<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="300249a3-ca20-bb73-e063-6394a90a982b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>SSD™ (1% Silver Sulfadiazine Cream)
 <br/>
      <br/>
SSD AF™ (1% Silver Sulfadiazine Cream)
</title>
   <effectiveTime value="20250310"/>
   <setId root="993aba22-60cc-4431-b529-90b4ef197848"/>
   <versionNumber value="13"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="829572556"/>
            <name>REMEDYREPACK INC.</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="30024c61-463e-bf66-e063-6394a90a779d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250310"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70518-2373" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>SSD Cream</name>
                        <formCode code="C28944" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CREAM"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Silver Sulfadiazine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="43598-210" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="936JST6JCN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2KR89I4H1Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4T6H12BN9U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PETROLATUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="13A4J4NH9I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYOXYL 40 STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0RE8K4LNJS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL MYRISTATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="06XEA2VD56" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITAN MONOOLEATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="10"/>
                              <denominator unit="g" value="1000"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="W46JY43EJR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILVER SULFADIAZINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0N7609K889" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SULFADIAZINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="25" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70518-2373-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20191021"/>
                                    <high value="20240525"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="50" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70518-2373-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C42794" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240619"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA018578" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20191021"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_c4068883-c529-4078-8c38-0e33867bae7c">
               <id root="db85f012-9adf-291e-e053-2a95a90a25a8"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRPITION</title>
               <text>
                  <paragraph>SSD™ (1% Silver Sulfadiazine Cream) and SSD AF™ (1%
                     Silver Sulfadiazine Cream), 1% are topical antibacterial preparations which
                     have as their active antimicrobial ingredient silver sulfadiazine. The active
                     moiety is contained within an opaque, white, water miscible cream base.
       
 
  <br/>
                     <br/>
                     Each 1000 grams of SSD/SSD AF Cream contains 10 grams of silver sulfadiazine.
       
 
  <br/>
                     <br/>
                     <content styleCode="bold">Inactive Ingrediants: </content>cetyl alcohol (SSD
                     Cream only), isopropyl myristate, polyoxyl 40 stearate, propylene glycol,
                     purified water, stearyl alcohol, sodium hydroxide, sorbitan monooleate, white
                     petrolatum; with 0.3% methyl paraben, as a preservative.
       
 
  <br/>
                     <br/> Silver
                     sulfadiazine has an emprical formula of
                        C
       
 
  <sub>10</sub>H
       
 
  <sub>9</sub>AgN
       
 
  <sub>4</sub>O
       
 
  <sub>2</sub>S, molecular weight
                     of 357.14 and structural formula as shown:
      

 </paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f1" referencedObject="mm1"/>
                  </paragraph>
               </text>
               <effectiveTime value="20220331"/>
               <component>
                  <observationMedia ID="mm1">
                     <text>Structure for silver sulfadiazine</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="silvadene-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_e59f0bab-0229-4557-84b7-33f97ee12074">
               <id root="db85f012-9ae0-291e-e053-2a95a90a25a8"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Silver sulfadiazine has broad antimicrobial activity.  It is
                     bactericidal for many gram-negative and gram-positive bacteria as well as being
                     effective against yeast.  Results from 
       
 
  <content styleCode="italics">in
                     vitro</content> testing are listed below.  Sufficient data have been obtained
                     to demonstrate that silver sulfadiazine will inhibit bacteria that are
                     resistant to other antimicrobial agents and that the compound is superior to
                     sulfadiazine.  Studies utilizing radioactive micronized silver sulfadiazine,
                     electron microscopy, and biochemical techniques have revealed that the
                     mechanism of action of silver sulfadiazine on bacteria differs from silver
                     nitrate and sodium sulfadiazine.  Silver sulfadiazine acts only on the cell
                     wall to produce its bactericidal effect.
      

 </paragraph>
                  <br/>
                  <paragraph>Results of 
       
 
  <content styleCode="italics">In Vitro</content> Testing With
                     Silver Sulfadiazine Cream, 1% Concentration of Silver Sulfadiazine 
       
 
  <br/>Number of
                     Sensitive Strains / Total Number of Strains Tested
       
 
  <br/>
                     <br/>
                  </paragraph>
                  <paragraph>Genus and Species                  50 micrograms/mL      100
                     micrograms/mL</paragraph>
                  <paragraph>Pseudomonas Aeruginosa            130/130                     130/130</paragraph>
                  <paragraph>Xanthomonas (Pseudomonas)</paragraph>
                  <paragraph>    Maltophilia                                 7/7                    
                             7/7</paragraph>
                  <paragraph>Enterobacter Species                   48/50                         
                     50/50</paragraph>
                  <paragraph>Enterobacter cloacae                   24/24                         
                     24/24</paragraph>
                  <paragraph>Klebsiella Species                       53/54                         
                     54/54</paragraph>
                  <paragraph>Escherichia Coli                          63/63                       
                       63/63</paragraph>
                  <paragraph>Serratia Species                         27/28                         
                     28/28</paragraph>
                  <paragraph>Proteus Mirabilis                        53/53                       
                        53/53</paragraph>
                  <paragraph>Morganella Morganii                   10/10                          
                     10/10</paragraph>
                  <paragraph>Providencia Rettgeri                    2/2                          
                        2/2</paragraph>
                  <paragraph>Proteus Vulgaris                         2/2                          
                         2/2</paragraph>
                  <paragraph>Providencia Species                    1/1                             
                     1/1</paragraph>
                  <paragraph>Citrobacter Species                   10/10                         
                     10/10</paragraph>
                  <paragraph>Acinetobacter Calcoaceticus      10/11                          11/11</paragraph>
                  <paragraph>Stahylococcus Aureus             100/101                       101/101</paragraph>
                  <paragraph>Staphylococcus Epidermidis      51/51                           51/51</paragraph>
                  <paragraph>B-Hemolytic Streptococcus         4/4                              4/4</paragraph>
                  <paragraph>Enterococcus Species              52/53                          53/53</paragraph>
                  <paragraph>Corynebacterium Diphtheriae       2/2                               2/2</paragraph>
                  <paragraph>Clostridium Perfringens               0/2                              
                     2/2</paragraph>
                  <paragraph>Clostridium Perfringens               0/2                              
                     2/2</paragraph>
                  <paragraph>Candida Albicans                    43/50                            
                     50/50</paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <paragraph>Silver sulfadiazine is not a carbonic anhydrase inhibitor and may be
                     useful in situations where such agents are contraindicated.</paragraph>
               </text>
               <effectiveTime value="20220331"/>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_5252e6ab-47e8-45f7-831f-6f0d65f02876">
               <id root="db85f012-9ae1-291e-e053-2a95a90a25a8"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as
                     an adjunct for the prevention and treatment of wound sepsis in patients with
                     second and third degree burns.</paragraph>
               </text>
               <effectiveTime value="20220331"/>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_43c07e9d-320d-4af7-9d85-30c1d3cf36a0">
               <id root="db85f012-9ae2-291e-e053-2a95a90a25a8"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Silver Sulfadiazine Cream is contraindicated in patients who are
                     hypersensitive to silver sulfadiazine or any of the other ingredients in the
                     preparation.</paragraph>
                  <paragraph>Because sulfonamide therapy is known to increase the possibility of
                     kernicterus, Silver Sulfadiazine Cream should not be used on pregnant women
                     approaching or at term, on premature infants, or on newborn infants during the
                     first 2 months of life.</paragraph>
               </text>
               <effectiveTime value="20220331"/>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_id_57ee8aaf-7ef7-42be-ab2c-fb8fbaead108">
               <id root="db85f012-9ae3-291e-e053-2a95a90a25a8"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNING</title>
               <text>
                  <br/>
                  <paragraph>There is a potential cross-sensitivity between silver sulfadiazine and
                     other sulfonamides.  If allergic reactions attributable to treatment with
                     silver sulfadiazine occur, continuation of therapy must be weighed against the
                     potential hazards of the particular allergic reaction.  </paragraph>
                  <paragraph>Fungal proliferation in and below the eschar may occur.  However, the
                     incidence of clinically reported fungal superinfection is low.</paragraph>
                  <paragraph>The use of Silver Sulfadiazine Cream in some cases of
                     glucose-6-phosphate dehydrogenase-deficient individuals may be hazardous, as
                     hemolysis may occur.
       
 
  <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20220331"/>
            </section>
         </component>
         <component>
            <section ID="i4i_precautions_id_5648c172-8274-406e-9aeb-d44db02d2b5f">
               <id root="db85f012-9ae4-291e-e053-2a95a90a25a8"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTION</title>
               <text>
                  <paragraph>If hepatic and renal functions become impaired and elimination of the
                     drug decreases accumulation may occur and discontinuation of Silver
                     Sulfadiazine Cream should be weighed against the therapeutic benefit being
                     achieved.</paragraph>
                  <paragraph>In considering the use of topical proteolytic enzymes in conjunction
                     with Silver Sulfadiazine Cream, the possibility should be noted that silver may
                     inactivate such enzymes.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Laboratory Tests: </content>In the treatment
                     of burn wounds involving extensive areas of the body, the serum sulfa
                     concentrations may approach adult therapeutic levels (8 to 12mg %).  Therefore,
                     in these patients it would be advisable to monitor serum sulfa concentrations. 
                     Renal function should be carefully monitored and the urine should be checked
                     for sulfa crystals.  
       
 
  <br/>
                  </paragraph>
                  <paragraph>Absorption of the propylene glycol vehicle has been reported to affect
                     serum osmolality, which may affect the interpretation of laboratory tests.
                     
       
 
  <br/>
                  </paragraph>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20220331"/>
            </section>
         </component>
         <component>
            <section ID="i4i_carcinogenesis_mutagenesis_fertility_id_28ce9a83-a8a9-45a6-a1a9-46fcba2ab5bd">
               <id root="db85f012-9ae5-291e-e053-2a95a90a25a8"/>
               <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
               <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
               <text>
                  <paragraph>Long-term dermal toxicity studies of 24 months duration in rats and 18
                     months in mice with concentrations of silver sulfadiazine three to ten times
                     the concentration in Silver Sulfadiazine Cream revealed no evidence of
                     carcinogenicity.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Pregnancy: Pregnancy Category B.</content> A
                     reproductive study has been performed in rabbits at doses up to three to ten
                     times the concentration of silver sulfadiazine in Silver Sulfadiazine Cream and
                     has revealed no evidence of harm to the fetus due to silver sulfadiazine. 
                     There are, however, no adequate and well-controlled studies in pregnant women. 
                     Because animal reproduction studies are not always predictive of human
                     response, this drug should be used during pregnancy only if clearly justified,
                     especially in pregnant women approaching or at term.  (See 
       
 
  <content styleCode="bold">CONTRAINDICATIONS</content>)
      

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Nursing Mother:</content> It is not known
                     whether Silver Sulfadiazine Cream is excreted in human milk.  However,
                     sulfonamides are known to be excreted in human milk and all sulfonamides
                     derivatives are known to increase the possibility of kernicterus.  Because of
                     the potential for serious adverse reactions in nursing infants from
                     sulfonamides, a decision should be made whether to discontinue nursing or to
                     discontinue the drug, taking into account the importance of the drug to the
                     mother.  
      

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Pediatric Use: </content> Safety and
                     effectiveness in children have not been established.  (See 
       
 
  <content styleCode="bold">CONTRAINDICATIONS</content>)
      

 </paragraph>
               </text>
               <effectiveTime value="20220331"/>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_42aadd43-5b9b-42d5-8129-5d6b85a7c7cc">
               <id root="db85f012-9ae6-291e-e053-2a95a90a25a8"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Several cases of transient leucopenia have been reported in patients
                     receiving silver sulfadiazine therapy.  Leucopenia associated with silver
                     sulfadiazine administration is primarily characterized by decreased neutrophil
                     count.  Maximal white blood cell depression occurs within two to four days of
                     initiation of therapy.  Rebound to normal leukocyte levels follows onset within
                     two to three days.  Recovery is not influenced by continuation of silver
                     sulfadiazine therapy.  The incidence of leucopenia in various reports averages
                     about 20%.  A higher incidence has been seen in patients treated concurrently
                     with cimetidine.</paragraph>
                  <paragraph>Other infrequently occurring events include skin necrosis, erythema
                     multiforme, skin discoloration, burning sensation, rashes, and interstitial
                     nephritis.  Reduction in bacterial growth after application of topical
                     antibacterial agents has been reported to permit spontaneous healing of deep
                     partial thickness burns by preventing conversion of the partial thickness to
                     full thickness by sepsis.  However, reduction in bacterial colonization has
                     caused delayed separation, in some cases necessitating escharotomy in order to
                     prevent contracture.</paragraph>
                  <paragraph>Absorption of silver sulfadiazine varies depending upon the percent of
                     body surface area and the extent of the tissue damage.  Although few have been
                     reported, it is possible that any adverse reaction associated with sulfonamides
                     may occur.  Some of the reactions which have been associated with sulfonamides
                     are as follows: blood dyscrasias, agranulocytosis, aplastic anemia,
                     thrombocytopenia, leucopenia, hemolytic anemia, dermatologic reactions,
                     allergic reactions, Stevens-Johnson syndrome, exfoliative dermatitis,
                     gastrointestinal reactions, hepatitis, hepatocellular necrosis, CNS reactions,
                     and toxic nephrosis.</paragraph>
               </text>
               <effectiveTime value="20220331"/>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_00df0cd9-b0e7-4f98-bd11-01ad26a3e636">
               <id root="db85f012-9ae7-291e-e053-2a95a90a25a8"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION: FOR TOPICAL USE ONLY - NOT FOR OPHTHALMIC USE:</title>
               <text>
                  <paragraph>Prompt institution of appropriate regimens for care of the burned
                     patient is of prime importance and includes the control of shock and pain.  The
                     burn wounds are then cleansed and debrided; Silver Sulfadiazine Cream is then
                     applied under sterile conditions.  The burn areas should be covered with Silver
                     Sulfadiazine Cream at all times.  The cream should be applied once to twice
                     daily to a thickness of approximately one sixteenth of an inch.  Whenever
                     necessary, the cream should be reapplied to any areas from which it has been
                     removed due to patient activity.  Administration may be accomplished in minimal
                     time because dressings are not required.  However, if individual patient
                     requirements make dressings necessary, they may be used.  Reapply immediately
                     after hydrotherapy.  Treatment with Silver Sulfadiazine Cream should be
                     continued until satisfactory healing has occurred or until the burn site is
                     ready for grafting.  The drug should not be withdrawn from the therapeutic
                     regimen while there remains the possibility of infection except if a
                     significant adverse reaction occurs.</paragraph>
               </text>
               <effectiveTime value="20220331"/>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_2d3d82bd-2088-4733-aa4d-21817d0597e9">
               <id root="1b5217ac-7185-e942-e063-6294a90a0d59"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>SSD™ (1% Silver Sulfadiazine) Cream: white to off-white cream.</paragraph>
                  <paragraph/>
                  <paragraph>NDC: 70518-2373-00</paragraph>
                  <paragraph>NDC: 70518-2373-01</paragraph>
                  <paragraph>PACKAGING: 25 g in 1 TUBE, TYPE 0</paragraph>
                  <paragraph>PACKAGING: 50 g in 1 TUBE, TYPE0</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Store at controlled room temperature 15° - 30°C (59° - 86°F)</paragraph>
                  <paragraph/>
                  <paragraph/>
                  <paragraph>Repackaged and Distributed By:</paragraph>
                  <paragraph>Remedy Repack, Inc.</paragraph>
                  <paragraph>625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762</paragraph>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20220331"/>
            </section>
         </component>
         <component>
            <section ID="id_link_e39dd3e5-6181-0c61-e053-2a95a90a9aba">
               <id root="21dcef59-8043-ec6f-e063-6394a90a2c01"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>DRUG: SSD Cream</paragraph>
                  <paragraph>GENERIC: Silver Sulfadiazine</paragraph>
                  <paragraph>DOSAGE: CREAM</paragraph>
                  <paragraph>ADMINSTRATION: TOPICAL</paragraph>
                  <paragraph>NDC: 70518-2373-0</paragraph>
                  <paragraph>NDC: 70518-2373-1</paragraph>
                  <paragraph>PACKAGING: 25 g in 1 TUBE</paragraph>
                  <paragraph>PACKAGING: 50 g in 1 TUBE</paragraph>
                  <paragraph>ACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>Silver Sulfadiazine 10g in 1000g</item>
                  </list>
                  <paragraph>INACTIVE INGREDIENT(S):</paragraph>
                  <list listType="unordered">
                     <item>WATER</item>
                     <item>CETYL ALCOHOL</item>
                     <item>STEARYL ALCOHOL</item>
                     <item>PETROLATUM</item>
                     <item>POLYOXYL 40 STEARATE</item>
                     <item>PROPYLENE GLYCOL</item>
                     <item>ISOPROPYL MYRISTATE</item>
                     <item>SORBITAN MONOOLEATE</item>
                     <item>METHYLPARABEN</item>
                  </list>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_1b5228a1-eec9-c13c-e063-6394a90a79d4"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph/>
               </text>
               <effectiveTime value="20220331"/>
               <component>
                  <observationMedia ID="img_1b5228a1-eec9-c13c-e063-6394a90a79d4">
                     <text>MM2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="SSD 1_70518-2373-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>